Does ENASIDENIB Cause Malignant neoplasm progression? 13 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 13 reports of Malignant neoplasm progression have been filed in association with ENASIDENIB (Idhifa). This represents 0.4% of all adverse event reports for ENASIDENIB.
13
Reports of Malignant neoplasm progression with ENASIDENIB
0.4%
of all ENASIDENIB reports
8
Deaths
1
Hospitalizations
How Dangerous Is Malignant neoplasm progression From ENASIDENIB?
Of the 13 reports, 8 (61.5%) resulted in death, 1 (7.7%) required hospitalization.
Is Malignant neoplasm progression Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for ENASIDENIB. However, 13 reports have been filed with the FAERS database.
What Other Side Effects Does ENASIDENIB Cause?
Death (650)
Off label use (213)
Fatigue (202)
Nausea (197)
Acute myeloid leukaemia (163)
Hospitalisation (149)
Diarrhoea (144)
Decreased appetite (122)
Platelet count decreased (113)
Drug ineffective (108)
What Other Drugs Cause Malignant neoplasm progression?
PEMBROLIZUMAB (10,111)
NIVOLUMAB (9,363)
ENZALUTAMIDE (4,696)
CARBOPLATIN (4,177)
EVEROLIMUS (3,789)
PACLITAXEL (3,484)
LETROZOLE (3,445)
IPILIMUMAB (3,296)
FULVESTRANT (3,221)
LENVATINIB (2,929)
Which ENASIDENIB Alternatives Have Lower Malignant neoplasm progression Risk?
ENASIDENIB vs ENBREL
ENASIDENIB vs ENCORAFENIB
ENASIDENIB vs ENDOXAN
ENASIDENIB vs ENDOXAN BAXTER
ENASIDENIB vs ENDOXAN INJ